GlassScriptPhysician profile
Kyoung Son
NPI 1376642132
$1,303.63
in general payments reported to CMS, 2019-2025
13 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.30 · 2020: $129 · 2021: $322 · 2022: $157 · 2023: $95.27 · 2024: $347 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $474.06 | 2020-2025 | Skyrizi, Rinvoq |
| Redhill Biopharma INC. | $174.79 | 2020-2025 | Talicia, Aemcolo |
| Takeda Pharmaceuticals U.S.A., INC. | $160.72 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.85 | 2019-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $94.44 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $77.72 | 2022-2023 | Sucraid |
| Daiichi Sankyo INC. | $68.95 | 2021-2024 | Injectafer |
| Vivus LLC | $56.19 | 2024-2025 | Qsymia |
| Intercept Pharmaceuticals, INC. | $27.87 | 2020 | |
| Janssen Biotech, INC. | $16.45 | 2023 | Stelara |
| Ipsen Biopharmaceuticals, INC | $15.41 | 2025 | |
| Gilead Sciences, INC. | $14.84 | 2020 | |
| Shionogi INC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyoung Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.